LAT2 Inhibitors

The chemicals listed above are not direct inhibitors of LAT2 but can potentially influence its activity or expression through various signaling pathways and cellular processes in T cells and natural killer cells. LAT2 is involved in the intracellular signaling cascades that follow T cell receptor (TCR) engagement, playing a role in the immune response. Immunosuppressive agents like Cyclosporine A and FK506 (Tacrolimus) inhibit calcineurin, a critical enzyme in T cell activation. By modulating T cell activation, these compounds could indirectly affect LAT2 signaling, as LAT2 is involved in the downstream signaling of activated T cells. Sirolimus (Rapamycin) targets the mTOR pathway, which is important in T cell metabolism and function. By influencing this pathway, Rapamycin could have an indirect effect on LAT2-mediated signaling.

Tyrosine kinase inhibitors such as Dasatinib, Nilotinib, and Ibrutinib can impact various aspects of T cell signaling. Since LAT2 is associated with tyrosine phosphorylation events in T cells, these inhibitors might indirectly modify LAT2 activity. Idelalisib, a PI3K inhibitor, and Sotrastaurin, a protein kinase C inhibitor, target other key enzymes in T cell signaling pathways. Their modulation of these pathways could potentially influence LAT2 signaling. Immunomodulatory drugs like Lenalidomide and Thalidomide alter the immune response, which could indirectly affect LAT2 activity in lymphocytes.Bortezomib, a proteasome inhibitor, and Venetoclax, a BCL-2 inhibitor, can influence cell survival and activation in immune cells, potentially impacting LAT2 signaling pathways.